statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc.(VTYX) of a Class Action Lawsuit and an Upcoming Deadline Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc.(VTYX) of...

Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc.(VTYX) of a Class Action Lawsuit and an Upcoming Deadline

VTYX IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 30 Deadline in...

VTYX IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTYX SHAREHOLDER ALERT...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTYX

Ventyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 30, 2024 to Discuss Your Rights - VTYX Ventyx Biosciences, Inc. Securities Fraud Class...

Ventyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 30, 2024 to Discuss Your Rights - VTYX

VTYX Investors Have Opportunity to Lead Ventyx Biosciences, Inc. Securities Fraud Lawsuit VTYX Investors Have Opportunity to Lead Ventyx Biosciences, Inc. Securities Fraud Lawsuit PR Newswire LOS...

VTYX Investors Have Opportunity to Lead Ventyx Biosciences, Inc. Securities Fraud Lawsuit

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx Biosciences ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors...

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx Biosciences

Ventyx Biosciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX Ventyx Biosciences, Inc. Sued for Securities Law Violations...

Ventyx Biosciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX

VTYX Investors Have Opportunity to Lead Ventyx Biosciences, Inc. Securities Fraud Lawsuit VTYX Investors Have Opportunity to Lead Ventyx Biosciences, Inc. Securities Fraud Lawsuit PR Newswire...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Biosciences, Inc. Lawsuit - VTYX The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Biosciences, Inc. Lawsuit - VTYX

Investors who lost over $100,000 with Ventyx Biosciences, Inc. (NASDAQ: VTYX) between October 2021 to November 2023, should contact the Shareholders Foundation in connection with Lawsuit Investors...

Investors who lost over $100,000 with Ventyx Biosciences, Inc. (NASDAQ: VTYX) between October 2021 to November 2023, should contact the Shareholders Foundation in connection with Lawsuit

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.

Volume	29,525.00
52-Wk High	$40.58
52-Wk Low	$1.87

VTYX Ventyx Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals